评估 2016/17 年和 2017/18 年美国流行的流感病毒对 baloxavir 的敏感性。
Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.
机构信息
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, United States of America.
Battelle Memorial Institute, Atlanta, United States of America.
出版信息
Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800666.
Abstract
The anti-influenza therapeutic baloxavir targets cap-dependent endonuclease activity of polymerase acidic (PA) protein. We monitored baloxavir susceptibility in the United States with next generation sequencing analysis supplemented by phenotypic one-cycle infection assay. Analysis of PA sequences of 6,891 influenza A and B viruses collected during 2016/17 and 2017/18 seasons showed amino acid substitutions: I38L (two A(H1N1)pdm09 viruses), E23G (two A(H1N1)pdm09 viruses) and I38M (one A(H3N2) virus); conferring 4-10-fold reduced susceptibility to baloxavir.
摘要
抗流感治疗药物巴洛沙韦针对聚合酶酸性（PA）蛋白的依赖 cap 的内切酶活性。我们通过补充表型单周期感染测定的下一代测序分析在美国监测巴洛沙韦的敏感性。对 2016/17 年和 2017/18 年期间收集的 6891 株流感 A 和 B 病毒的 PA 序列进行分析显示，氨基酸取代：I38L（两种 A(H1N1)pdm09 病毒）、E23G（两种 A(H1N1)pdm09 病毒）和 I38M（一种 A(H3N2)病毒），对巴洛沙韦的敏感性降低了 4-10 倍。
相似文献
1
Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.评估 2016/17 年和 2017/18 年美国流行的流感病毒对 baloxavir 的敏感性。
Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800666.
2
Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.在日本2022 - 2023年流感季节期间，巴洛沙韦酯治疗前后对具有聚合酶酸性亚基替代的甲型（H3N2）流感病毒的检测。
Antiviral Res. 2024 Sep;229:105956. doi: 10.1016/j.antiviral.2024.105956. Epub 2024 Jul 4.
3
Impact of the Baloxavir-Resistant Polymerase Acid I38T Substitution on the Fitness of Contemporary Influenza A(H1N1)pdm09 and A(H3N2) Strains.抗病毒药物耐药聚合酶酸性 I38T 取代对当代甲型流感 A(H1N1)pdm09 和 A(H3N2) 株适应性的影响。
J Infect Dis. 2020 Jan 1;221(1):63-70. doi: 10.1093/infdis/jiz418.
4
Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018.全球 2017-2018 年人类流感病毒对神经氨酸酶抑制剂和帽依赖性内切酶抑制剂巴洛沙韦耐药性的最新情况。
Antiviral Res. 2020 Mar;175:104718. doi: 10.1016/j.antiviral.2020.104718. Epub 2020 Jan 28.
5
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018.日本 2018 年 12 月新型依赖于帽子结构的内切酶抑制剂 baloxavir 敏感性降低的甲型 H3N2 流感病毒的检测
Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800698.
6
Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission.甲型流感病毒聚合酶酸性蛋白 E23G/K 取代削弱了与关键巴洛沙韦药物结合的关键接触点，对复制和传播的影响最小。
PLoS Pathog. 2022 Jul 13;18(7):e1010698. doi: 10.1371/journal.ppat.1010698. eCollection 2022 Jul.
7
Rapid detection of an I38T amino acid substitution in influenza polymerase acidic subunit associated with reduced susceptibility to baloxavir marboxil.快速检测与对巴洛沙韦耐药性降低相关的流感聚合酶酸性亚单位 I38T 氨基酸取代。
Influenza Other Respir Viruses. 2020 Jul;14(4):436-443. doi: 10.1111/irv.12728. Epub 2020 Feb 16.
8
Influenza A and B viruses with reduced baloxavir susceptibility display attenuated in vitro fitness but retain ferret transmissibility.对巴洛沙韦敏感性降低的甲型和乙型流感病毒在体外适应性减弱，但仍保留在雪貂中的传播能力。
Proc Natl Acad Sci U S A. 2020 Apr 14;117(15):8593-8601. doi: 10.1073/pnas.1916825117. Epub 2020 Mar 26.
9
High throughput profiling identified PA-L106R amino acid substitution in A(H1N1)pdm09 influenza virus that confers reduced susceptibility to baloxavir in vitro.高通量分析鉴定出 A(H1N1)pdm09 流感病毒中的 PA-L106R 氨基酸取代，该取代导致体外对巴洛沙韦的敏感性降低。
Antiviral Res. 2024 Sep;229:105961. doi: 10.1016/j.antiviral.2024.105961. Epub 2024 Jul 13.
10
Replicative Fitness of Seasonal Influenza A Viruses With Decreased Susceptibility to Baloxavir.对巴洛沙韦敏感性降低的季节性流感 A 病毒的复制适应性。
J Infect Dis. 2020 Jan 14;221(3):367-371. doi: 10.1093/infdis/jiz472.
引用本文的文献
1
Effects of Baloxavir Marboxil Plus Neuraminidase Inhibitor vs Neuraminidase Inhibitor in High-risk Patients Hospitalized With Severe Influenza: A Post Hoc Analysis of the Flagstone Trial.巴洛沙韦酯联合神经氨酸酶抑制剂与神经氨酸酶抑制剂对重症流感住院高危患者的影响：一项针对FLAFLAGSTONE试验的事后分析 。
Open Forum Infect Dis. 2025 Jul 25;12(8):ofaf439. doi: 10.1093/ofid/ofaf439. eCollection 2025 Aug.
2
Global update on the susceptibilities of influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2020-2023.2020 - 2023年流感病毒对神经氨酸酶抑制剂和帽依赖性核酸内切酶抑制剂巴洛沙韦敏感性的全球最新情况
Antiviral Res. 2025 Sep;241:106217. doi: 10.1016/j.antiviral.2025.106217. Epub 2025 Jun 24.
3
Antiviral Susceptibility of Swine-Origin Influenza A Viruses Isolated from Humans, United States.美国从人分离的猪源流感病毒的抗病毒敏感性。
Emerg Infect Dis. 2024 Nov;30(11):2303-2312. doi: 10.3201/eid3011.240892. Epub 2024 Oct 8.
4
Baloxavir Resistance Markers in Influenza A and B Viruses in the Americas.美洲甲型和乙型流感病毒中的巴洛沙韦耐药标志物
Drug Healthc Patient Saf. 2024 Sep 14;16:105-113. doi: 10.2147/DHPS.S470868. eCollection 2024.
5
Sequence analysis of isolated strains of herpes zoster virus among patients with shingles.带状疱疹患者中分离出的带状疱疹病毒菌株的序列分析。
Iran J Microbiol. 2024 Aug;16(4):524-535. doi: 10.18502/ijm.v16i4.16312.
6
Multiple transatlantic incursions of highly pathogenic avian influenza clade 2.3.4.4b A(H5N5) virus into North America and spillover to mammals.高致病性禽流感 clade 2.3.4.4b 亚型（H5N5）病毒多次跨越大西洋传入北美洲，并溢出到哺乳动物。
Cell Rep. 2024 Jul 23;43(7):114479. doi: 10.1016/j.celrep.2024.114479. Epub 2024 Jul 13.
7
Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.新兴甲型流感病毒对神经氨酸酶和帽子依赖性内切酶抑制剂的基因型和表型敏感性。
Antiviral Res. 2024 Sep;229:105959. doi: 10.1016/j.antiviral.2024.105959. Epub 2024 Jul 8.
8
Influenza C virus susceptibility to antivirals with different mechanisms of action.C 型流感病毒对不同作用机制抗病毒药物的敏感性。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0172723. doi: 10.1128/aac.01727-23. Epub 2024 Apr 8.
9
The impact of PA/I38 substitutions and PA polymorphisms on the susceptibility of zoonotic influenza A viruses to baloxavir.PA/I38 取代和 PA 多态性对人畜共患流感 A 病毒对巴洛沙韦敏感性的影响。
Arch Virol. 2024 Jan 12;169(2):29. doi: 10.1007/s00705-023-05958-5.
10
Vaccination and Antiviral Treatment against Avian Influenza H5Nx Viruses: A Harbinger of Virus Control or Evolution.针对H5Nx禽流感病毒的疫苗接种与抗病毒治疗：病毒控制或进化的先兆
Vaccines (Basel). 2023 Oct 24;11(11):1628. doi: 10.3390/vaccines11111628.
本文引用的文献
1
Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018.对 2011-2018 年甲型流感病毒（H3N2）抗原进化的认识。
Sci Rep. 2019 Feb 25;9(1):2676. doi: 10.1038/s41598-019-39276-1.
2
Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil.流感病毒对新型帽依赖性内切酶抑制剂巴洛沙韦酯的敏感性。
Front Microbiol. 2018 Dec 6;9:3026. doi: 10.3389/fmicb.2018.03026. eCollection 2018.
3
In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.体外鉴定巴洛沙韦酸：一种新型流感病毒聚合酶 PA 亚单位依赖帽结构的内切核酸酶抑制剂。
Antiviral Res. 2018 Dec;160:109-117. doi: 10.1016/j.antiviral.2018.10.008. Epub 2018 Oct 11.
4
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.巴洛沙韦玛波西利治疗成人和青少年单纯性流感。
N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.
5
Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.描述使用内切酶抑制剂巴洛沙韦治疗诱导的流感病毒变异体。
Sci Rep. 2018 Jun 25;8(1):9633. doi: 10.1038/s41598-018-27890-4.
6
Mapping of the US Domestic Influenza Virologic Surveillance Landscape.美国国内流感病毒学监测格局的描绘。
Emerg Infect Dis. 2018 Jul;24(7):1300-6. doi: 10.3201/eid2407.180028. Epub 2018 Jul 17.
7
Baloxavir: First Global Approval.巴洛沙韦：全球首次获批
Drugs. 2018 Apr;78(6):693-697. doi: 10.1007/s40265-018-0899-1.
8
Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease.流感病毒 PA 内切酶中二酮酸抑制剂 L-742,001 结合口袋的突变分析。
J Virol. 2013 Oct;87(19):10524-38. doi: 10.1128/JVI.00832-13. Epub 2013 Jul 3.
9
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.2009年甲型H1N1流感大流行病毒体外药敏的综合评估。
Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.
10
Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses.焦磷酸测序作为检测季节性甲型流感病毒中神经氨酸酶抑制剂耐药分子标志物的工具。
Antiviral Res. 2009 Jan;81(1):16-24. doi: 10.1016/j.antiviral.2008.08.008. Epub 2008 Oct 7.
Zotero 插件